Luo et al. identified a biomarker panel (phenylalanyl-tryptophan and glycocholate) that had a better diagnostic value compared to AFP for distinguishing HCC patients from a high-risk cohort of cirrhotic patients [14]. The gene discussed is AFP; the disease is hepatocellular carcinoma.